Unlock instant, AI-driven research and patent intelligence for your innovation.

T cell receptor of HLA-A11 restricted hepatitis B virus HBc141-151 epitope peptide and application thereof

A technology of HLA-A11 and cell receptors, applied in the field of T cell receptors

Active Publication Date: 2021-06-11
INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in-depth research is urgently needed in the treatment of HLA-A11-restricted liver cancer, which is dominated by the Chinese population.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T cell receptor of HLA-A11 restricted hepatitis B virus HBc141-151 epitope peptide and application thereof
  • T cell receptor of HLA-A11 restricted hepatitis B virus HBc141-151 epitope peptide and application thereof
  • T cell receptor of HLA-A11 restricted hepatitis B virus HBc141-151 epitope peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1. Acquisition and application of TCR-T cells

[0065]1. Screening of HLA-A11 / hTAP-LMP transgenic mice to obtain A11-restricted HBV-specific TCR sequences

[0066] 1. 100 μL containing 100 μg polypeptide HBc 123-157 and 100 μg helper polypeptide HBc 128-140 PBS buffer and 100 μ LIFA were mixed and emulsified; then subcutaneously injected into HLA-A11 / hTAP-LMP transgenic mice at multiple points. HLA-A11 / hTAP-LMP transgenic mice will induce HBc-specific 141-151 Primary CTL immune response to epitopes.

[0067] 2. On the 14th day after completing step 1, inject pAAV / HBV1.2 plasmid into the tail vein of HLA-A11 / hTAP-LMP transgenic mice by tail vein high pressure injection method, and inject 10 μg pAAV / HBV1.2 plasmid into each mouse .

[0068] The pAAV / HBV1.2 plasmid contains 1.2 copies of the genome of HBV virus, and can be used to simulate the early stages of HBV in mice by transiently transfecting mouse liver cells and expressing hepatitis B virus antigens an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a T cell receptor of an HLA-A11 restricted hepatitis B virus HBc141-151 epitope peptide and an application thereof. The T cell receptor comprises an alpha chain and a beta chain; the alpha chain comprises three complementarity determining regions, and the amino acid sequences of the three complementarity determining regions are respectively shown as the 48th to 53rd sites, the 71st to 77th sites and the 112th to 121st sites of SEQ ID No.2; the beta chain comprises three complementary determining regions, and the amino acid sequences of the three complementary determining regions are respectively shown as the 46th to 50th sites, the 68th to 73rd sites and the 111st to 122nd sites of SEQ ID No.4. The experiments prove that the T cell receptor not only has HBV polypeptide epitope-dependent activation and proliferation capacity, but also has good in-vivo and in-vitro activity of killing target cells, and also can effectively eliminate chronic HBV infection in vivo. The method has very important application value.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to HLA-A11 restricted hepatitis B virus HBc 141-151 T cell receptors for epitope peptides and their applications. Background technique [0002] Hepatocellular Carcinoma (HCC), referred to as liver cancer, has hidden clinical manifestations and lacks typical symptoms in the early stage. Although the diagnosis and treatment of liver cancer have made some progress in recent years, its prognosis is still unsatisfactory, and the five-year survival rate is extremely low. The reason is that, on the one hand, liver cancer is not sensitive to current chemotherapy drugs, and most liver cancer patients lack effective treatment methods; on the other hand, liver cancer is often diagnosed in the late stage of the disease, which excludes local ablation, which can improve patient outcomes. method of illness. At present, surgical resection and liver transplantation are still the most effective methods f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/725C12N15/12C12N15/867C12N5/10A61K35/17A61P31/20
CPCC07K14/7051A61P31/20C12N15/86C12N5/0636C12N2510/00C12N2740/10043C12N2740/15043A61K39/4611A61K39/4632A61K39/464838A61K2239/38C07K14/435C07K14/705A61P35/00A61K38/17C12N15/63C12N2740/16043C07K14/005C12N2730/10134C12N2730/10122C12N5/10
Inventor 周旭宇魏训东徐威张建华黄满
Owner INST OF MICROBIOLOGY - CHINESE ACAD OF SCI